Freise J
Fortschr Med. 1983 Aug 25;101(31-32):1432-6.
In order to evaluate the efficacy and safety of gabexate mesilate (FOY = [ethyl-4-(6-guanidinohexanoyloxy) benzoate methane sulfonate]), a synthetic inhibitor of various proteases as well as phospholipase A 2, 17 patients with acute pancreatitis were treated with FOY in doses of 3 X 150 mg/day per i.v. perfusor. The clinical course of the disease and the laboratory findings were compared with the results of a control group of 21 patients also suffering from acute pancreatitis. 30% of the patients in the FOY-group and 40% in the control group had different complications during the first week after admission to the hospital. The laboratory findings in the two groups revealed that alpha-amylase levels in serum and urine in the FOY-group were significantly lower than in the control group. Side effects of the drug were not observed. FOY may be considered a promising drug for treatment of acute pancreatitis in view of its few side effects and especially with regard to its mode of action.
为了评估甲磺酸加贝酯（FOY = [4-(6-胍基己酰氧基)苯甲酸乙酯甲磺酸盐]）的疗效和安全性，甲磺酸加贝酯是一种多种蛋白酶及磷脂酶A2的合成抑制剂，17例急性胰腺炎患者接受了甲磺酸加贝酯治疗，剂量为每日3次，每次150mg，通过静脉输液泵给药。将该疾病的临床病程及实验室检查结果与另一组同样患有急性胰腺炎的21例患者的结果进行比较。在入院后的第一周，甲磺酸加贝酯组30%的患者及对照组40%的患者出现了不同的并发症。两组的实验室检查结果显示，甲磺酸加贝酯组血清和尿液中的α淀粉酶水平显著低于对照组。未观察到该药物的副作用。鉴于甲磺酸加贝酯副作用少，尤其是考虑到其作用方式，它可被视为治疗急性胰腺炎的一种有前景的药物。
